Compare AstraZeneca plc (AZN) vs YieldMax Universe Fund of Option Income ETFs (YMAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs YieldMax Universe Fund of Option Income ETFs — how do they compare? AstraZeneca plc trades at $157.98 (market cap $245.16B), while YieldMax Universe Fund of Option Income ETFs trades at $7.71. The key difference: AstraZeneca plc pays a 2.02% dividend while YieldMax Universe Fund of Option Income ETFs pays none, and AstraZeneca plc is trading nearer its 52-week high, YieldMax Universe Fund of Option Income ETFs nearer its low. Which is the better fit depends on your goals.
| AZN | YMAX | |
|---|---|---|
Market Cap | $245.16B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $209.48 | $13.26 |
52-Week Low | $147.06 | $7.27 |
Enterprise Value | $272.43B | — |
Dividend Yield | 2.02% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $157.24, down 0.95% on the day, amid bearish technical signals and merger speculation. The company shows strong fundamentals with revenue growth from $44.4B in 2022 to $58.7B in 2025 and net income margin improving to 17.4%. Recent earnings beats and a 47.5% analyst buy rating contrast with technical indicators showing selling pressure and legal investigations creating near-term uncertainty.
AZN presents a mixed outlook with strong pharmaceutical fundamentals offset by technical weakness and merger-related volatility. The investment case hinges on continued earnings growth and strategic execution, while risks include integration challenges from potential M&A and ongoing legal scrutiny. Wall Street remains predominantly bullish despite recent price pressure.
YMAX trades at $7.63, down 1.04% today, with a bullish technical signal but mixed momentum indicators. The ETF maintains a consistent weekly dividend distribution schedule, though recent news highlights concerns over fee structures impacting payouts. Support and resistance levels cluster around $8, indicating potential consolidation near current prices.
Outlook remains cautious due to high fees eroding yields and technical overbought signals. Risks include cost inefficiencies and dependency on market volatility for strategy performance. Analyst sentiment is mixed, balancing income appeal against structural expenses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About YieldMax Universe Fund of Option Income ETFs
YMAX is an actively managed 'fund of funds' that provides equal-weighted exposure to the full suite of YieldMax option income ETFs. It is designed to generate high current income by aggregating the premiums from various single-stock and thematic covered call strategies, offering a diversified approach to high-yield option investing.
Read more on YMAX →
